Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
Syneos Purchased For $7.1bn In Go-Private Deal
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
